IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Kalvista Pharmaceuticals Inc (KALV)

CUSIP: 483497103 | NYSE | Healthcare · Biotechnology | Small Cap | 431 institutional holders

Quarters

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13G/ATang Capital Partners, LP00.0%No shares heldJun 30, 2026No 13F filer matched
13D/AFrazier Life Sciences Public Fund, L.P.
with Fhmls X, L.L.C., Frazier Life Sciences X, L.P., Fhmls X, L.P., +8 more
1,249,1652.3%−2,217,356May 19, 2026No 13F filer matched
13G/ATang Capital Partners, LP0
0.0% of class · Jun 30, 2026No shares held
No 13F filer matched
13D/AFrazier Life Sciences Public Fund, L.P.1,249,165
2.3% of class · May 19, 2026−2,217,356
with Fhmls X, L.L.C., Frazier Life Sciences X, L.P., Fhmls X, L.P., +8 more
No 13F filer matched

Institutional Holders — Q2 2026

IFP Advisors, Inc7
0.0% of portfolio›$189
StyleTurnoverLocationFiled
IFP Advisors, Inc
7$1890.0%GrowthLowTampa, FL2026-07-20